Stemgenics Overview

  • Founded
  • 2008
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $445K
Latest Deal Amount
  • Investors
  • 1

Stemgenics General Information

Description

Owner and operator of a biotechnology company for skin treatment. The company offers regeneration of a variety of tissues of the human body to convert mature cells into personalized stem cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Angel-Backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare
Primary Office
  • 454 North 34th Street
  • Suite 100
  • Seattle, WA 98103
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Stemgenics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Angel (individual) 12-Jul-2018 $445K 00.000 000.00 Completed Generating Revenue
3. Angel (individual) 29-Dec-2015 00.00 00.00 000.00 Completed Startup
2. Angel (individual) 03-Jan-2014 $1.1M $1.1M Completed Generating Revenue
1. Grant 28-Jun-2012 $150K Completed Startup
To view Stemgenics’s complete valuation and funding history, request access »

Stemgenics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B2a 000,000 00.00 00.00 00 00.00 0.000
Series B2d 0,000,000 00.00 00.00 00 00.00 00
Series B2c 0,000,000 00.00 00.00 00 00.00 00
Series B2b 000,000 00.00 00.00 00 00.00 00
Series B 000,000 00.00 00.00 00 00.00 0.000
Series A 2,566,655 $0.43 $0.43 1x $0.43 25.56%
Seed 2,310,000 $0.03 $0.03 1x $0.03 23%
To view Stemgenics’s complete cap table history, request access »

Stemgenics Patents

Stemgenics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3463316-A2 Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use Pending 03-Jun-2016 00000000000
EP-3463316-A4 Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use Pending 03-Jun-2016 00000000000
US-20210154323-A1 Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use Pending 03-Jun-2016 00000000000
US-20180223260-A1 Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use Abandoned 21-Oct-2011 0000000000 0
AU-2018203848-A1 Functionalized nanoparticles for intracellular delivery of biologically active molecules Abandoned 21-Oct-2011 G01N33/54353
To view Stemgenics’s complete patent history, request access »

Stemgenics Executive Team (3)

Name Title Board Seat Contact Info
Frederick Hagen Ph.D Chief Executive Officer
Andranik Aprikyan Ph.D Co-Founder, Chief Scientific Officer, Executive Vice President and Board Member
Mushegh Hovhannisyan Executive Officer and Board Member
To view Stemgenics’s complete executive team members history, request access »

Stemgenics Board Members (1)

Name Representing Role Since
Mushegh Hovhannisyan Stemgenics Executive Officer and Board Member 000 0000
To view Stemgenics’s complete board members history, request access »

Stemgenics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Stemgenics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Science Foundation Government 000 0000 000000 0
To view Stemgenics’s complete investors history, request access »